SUTRO BIOPHARMA, INC. (STRO) Spending and interest coverage
- R&D / revenue · 12 months: Value 316.71%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 14.83%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 316.71% | Research and development expense / revenue. Period ending 2026-06-30. $144.74M ÷ $45.70M × 100 ≈ 316.71% |
| Stock-based compensation / revenue · 12 months | 14.83% | Share-based compensation / revenue. Period ending 2026-06-30. $6.78M ÷ $45.70M × 100 ≈ 14.83% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 144.74M USD | Research and Development Expense |
| Revenue | 45.70M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 6.78M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -146.05M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $144.74M | $45.70M | $6.78M | $-146.05M | (m) | 316.71% | 14.83% | (m) | (m) |
| 2026-03-31 | $151.37M | $99.61M | $10.03M | $-119.51M | (m) | 151.97% | 10.07% | (m) | (m) |
| 2025-12-31 | $166.42M | $102.48M | $14.01M | $-158.37M | (m) | 162.38% | 13.67% | (m) | (m) |
| 2025-09-30 | $200.81M | $105.65M | $18.27M | $-185.58M | (m) | 190.08% | 17.29% | (m) | (m) |
| 2025-06-30 | $223.07M | $104.47M | $23.26M | $-205.04M | (m) | 213.52% | 22.27% | (m) | (m) |
| 2025-03-31 | $246.76M | $66.43M | $24.16M | $-250.38M | (m) | 371.44% | 36.36% | (m) | (m) |
| 2024-12-31 | $252.04M | $62.04M | $24.69M | $-238.45M | (m) | 406.24% | 39.79% | (m) | (m) |
| 2024-09-30 | $234.77M | $160.96M | $25.00M | $-130.04M | (m) | 145.86% | 15.53% | (m) | (m) |
| 2024-06-30 | $218.33M | $169.36M | $24.45M | $-106.14M | (m) | 128.92% | 14.44% | (m) | (m) |
| 2024-03-31 | $197.90M | $154.06M | $24.95M | $-103.63M | (m) | 128.45% | 16.20% | (m) | (m) |
| 2023-12-31 | $180.43M | $153.73M | $24.91M | $-89.28M | (m) | 117.36% | 16.20% | (m) | (m) |
| 2023-09-30 | $169.79M | $48.64M | $24.54M | $-181.65M | (m) | 349.07% | 50.44% | (m) | (m) |
| 2023-06-30 | $155.84M | $56.87M | $25.32M | $-158.85M | (m) | 274.05% | 44.52% | (m) | (m) |
| 2023-03-31 | $146.58M | $74.55M | $25.35M | $-132.05M | (m) | 196.62% | 34.01% | (m) | (m) |
| 2022-12-31 | $137.17M | $67.77M | $26.30M | $-128.94M | (m) | 202.40% | 38.81% | (m) | (m) |
| 2022-09-30 | $123.96M | $69.79M | $27.34M | $-114.76M | (m) | 177.61% | 39.17% | (m) | (m) |
| 2022-06-30 | $118.85M | $53.16M | $27.05M | $-128.22M | (m) | 223.56% | 50.88% | (m) | (m) |
| 2022-03-31 | $111.83M | $53.12M | $26.26M | $-118.65M | (m) | 210.53% | 49.44% | (m) | (m) |
| 2021-12-31 | $104.40M | $61.88M | $23.24M | $-98.52M | (m) | 168.71% | 37.56% | (m) | (m) |
| 2021-09-30 | $97.21M | $59.50M | $19.44M | $-88.33M | (m) | 163.37% | 32.67% | (m) | (m) |
| 2021-06-30 | $89.97M | $68.81M | $16.06M | $-64.27M | (m) | 130.75% | 23.34% | (m) | (m) |
| 2021-03-31 | $81.90M | $50.23M | $13.16M | $-70.89M | (m) | 163.06% | 26.20% | (m) | (m) |
| 2020-12-31 | $76.96M | $42.72M | $11.92M | $-71.06M | (m) | 180.14% | 27.89% | (m) | (m) |
| 2020-09-30 | $71.61M | $45.75M | $11.51M | $-61.00M | (m) | 156.54% | 25.17% | (m) | (m) |
| 2020-06-30 | $69.15M | $40.20M | $11.28M | $-63.11M | (m) | 172.00% | 28.06% | (m) | (m) |
| 2020-03-31 | $68.05M | $41.26M | $10.73M | $-60.38M | (m) | 164.94% | 26.01% | (m) | (m) |
| 2019-12-31 | $65.61M | $42.74M | $10.31M | $-55.47M | (m) | 153.53% | 24.13% | (m) | (m) |
| 2019-09-30 | $63.01M | $50.52M | $9.70M | $-43.96M | (m) | 124.72% | 19.20% | (m) | (m) |
| 2019-06-30 | $58.75M | $46.08M | $7.14M | $-41.38M | (m) | 127.51% | 15.50% | (m) | (m) |
| 2019-03-31 | $56.36M | $41.26M | $4.89M | $-39.79M | (m) | 136.61% | 11.86% | (m) | (m) |
| 2018-12-31 | $54.26M | $38.42M | $2.87M | $-37.22M | $1.62M | 141.24% | 7.48% | -22.93× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $33.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $42.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $54.64M | $51.74M | $1.39M | $-19.27M | $612.00K | 105.60% | 2.69% | -31.49× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $43.55M | $59.73M | $968.00K | $1.36M | $0.00 | 72.91% | 1.62% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |